title: Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens.
abstract: We present two cases of advanced ovarian cancer treated with neoadjuvant chemotherapy with standard tri-weekly carboplatin and paclitaxel. Therapy was converted to weekly regimens because of disease progression, resulting in disease response. Weekly regimens could overcome drug resistance and this strategy should be attempted before abandoning first-line chemotherapy in favor of palliation.
authors: Department of Gynecology and Obstetrics, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
authors: Claudia
authors: C
authors: Marchetti
authors: Filippo
authors: F
authors: Bellati
authors: Angela
authors: A
authors: Musella
authors: Chiara
authors: C
authors: Napoletano
authors: Giorgia
authors: G
authors: Perniola
authors: Violante
authors: V
authors: Di Donato
authors: Sandro
authors: S
authors: Pignata
authors: Marianna
authors: M
authors: Nuti
authors: Pierluigi Benedetti
authors: PB
authors: Panici
mesh_terms: D018394:CA-125 Antigen / Q000097:blood; D016190:Carboplatin / Q000008:administration & dosage*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008565:Membrane Proteins / Q000097:blood; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage*
chemical_list: D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D016190:Carboplatin; D017239:Paclitaxel